Skip to content

Should you be taking peptides?

Even a pro-peptide researcher has one big reservation

Levels <[email protected]>

Other

Share
Sent with SendGrid Sends about 3 a week All facts

Levels promotes a discussion on the science behind peptides, featuring an interview with Dr. Christopher Robinson, a Johns Hopkins physician-scientist. The company highlights the lack of human evidence for popular peptides like BPC-157 and notes that many are repurposed or abandoned drugs. Levels presents five key takeaways to educate readers on the peptide market.

What the raw message shows

From the headers

Sent with
SendGrid See it in the headers

Across Levels's email

Sends
About 3 a week
DMARC
Enforced, reject

Mail failing authentication is refused.

The copy

411 words · about 2 min to read · 2 buttons

What one extra drink does to your night

The peptide boom is running ahead of the science

On October 28, HHS said it would stop taking action against licensed pharmacies that compound six popular peptides, including BPC-157 and TB-500, the pair sold online as the "Wolverine stack." For a market that's run on gray-market vials for years, that sounds like a turning point. To sort out what changed and what didn't, we sat down with Dr. Christopher Robinson, a Johns Hopkins physician-scientist who specializes in pain and regenerative medicine. Robinson calls himself pro-peptide and has applied for funding to test one. That's what makes his read on the evidence worth hearing.

Button The truth about peptides →

Five Key Takeaways

1. "Peptide" describes a size, not a breakthrough.

Any chain of 40 or fewer amino acids counts, so insulin, growth hormone, and GLP-1 drugs like semaglutide are all peptides. The compounds getting the buzz are a lightly studied corner of a very old category.

2. Human evidence for BPC-157 is nearly nonexistent.

Thirty years of animal research comes almost entirely from one lab in Croatia. Independent reviews count fewer than 30 people across all the human studies, and no randomized trial has been completed.

3. Many popular peptides are repurposed or abandoned drugs.

Tesamorelin is approved only to reduce abdominal fat in people with HIV-related lipodystrophy, and Melanotan II, sold for tanning, was abandoned in development before the wellness market picked it up. Using compounds like these for recovery or longevity goes well beyond what they were tested for.

4. The new policy still falls short of approval.

None of the six is FDA-approved or formally cleared for compounding, and the policy is interim. The FDA's own scientists had also recommended against all seven peptides its advisory panel reviewed. Still, a prescription from a licensed compounding pharmacy is safer than a "research use only" vial of unknown origin.

5. The trial that would settle it is simple and unfunded.

Robinson wants to test BPC-157 against a placebo for knee osteoarthritis. He'd measure function with wearables and cartilage with MRI, rather than relying on pain scores. Until data like that exists, his advice for friends and patients considering a peptide they find online or from a dude at the gym: don’t.

Button Read the full conversation →

Looking to understand more about your metabolic health?

Explore our health news and advice site, Metabolic Insights

228 Park Ave South, PMB 63877, New York, NY 10003

The words as text: what a screen reader can follow, and all there is when images don't load.

What the headers say

Read from the message's own headers, as it arrived.

Came from
o24.sg.m.dripemail2.com · 192.254.112.219

SendGrid's sending servers

SPF
Pass for drip.levels.com
DKIM
  • Pass signed by levels.com
DMARC
Pass for levels.com

Policy: reject

Unsubscribe
One-click

Meets the Gmail and Yahoo rule for bulk senders.

Complaints
No feedback-loop header
Show all 17 headers

As received, minus the delivery side: the archive's own addresses show as [recipient], its mail servers as [receiver], signatures are left out and unsubscribe links trimmed to their host.

Route

Received
from o24.sg.m.dripemail2.com (192.254.112.219) by [receiver] (cloudflare) id mZDcn1eSVplw for <[recipient]>; Thu, 19 Nov 2026 16:00:33 +0000
Received
by recvd-7fd4c8c657-zrk8z with SMTP id recvd-7fd4c8c657-zrk8z-1-6AFF1609-2D 2026-11-19 15:30:17.121062036 +0000 UTC m=+746273.402656237
Received
from MTMxMTA3NDc (unknown) by geopod-ismtpd-11 (SG) with HTTP id rSWItUiAR5GwvUB2WSoaVw Thu, 19 Nov 2026 15:30:17.100 +0000 (UTC)

Authentication

Received-SPF Authentication result
pass ([receiver]: domain of [email protected] designates 192.254.112.219 as permitted sender) receiver=[receiver]; client-ip=192.254.112.219; envelope-from="[recipient]@drip.levels.com"; helo=o24.sg.m.dripemail2.com;
Authentication-Results Authentication result
[receiver]; dkim=pass header.d=levels.com header.s=s1 header.b=SJVsGAkx; dmarc=pass header.from=levels.com policy.dmarc=reject; spf=none ([receiver]: no SPF records found for [email protected]) smtp.helo=o24.sg.m.dripemail2.com; spf=pass ([receiver]: domain of [email protected] designates 192.254.112.219 as permitted sender) smtp.mailfrom="[recipient]@drip.levels.com"; arc=none smtp.remote-ip=192.254.112.219

Platform

X-Drip-SendingAccount
4080355
X-SG-EID Identifies SendGrid
u001.79kJZC85z/WE9t9nOmpiHosf7qU1Au+mrKy3jytIn8sMbSWRTgBdv9q1OykY6JKWUyE26878N4YhksNNJA9CVd+kedr9PsHLzXLtLLuobsuEPc/+gMorUaccn45Lot/m2nLURO9Dzl0N0EbDpobORW0MYeWNTHvlLxEgRfz7r2HFSvAZxfSXDSfBLIBbZrcMBWL5aHcHRsn6GHJEoqO3Z8QzCeYcNabtoGqZlr4PBJw=
X-SG-ID Identifies SendGrid
u001.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
X-Entity-ID
u001.dEl2Z4sQ4dqI57TjhSSBBA==

Unsubscribe and feedback

List-Unsubscribe
<mailto:…@unsubscribe.dripemail3.com>, <https://unsubscribe.dripemail3.com/…>
List-Unsubscribe-Post
List-Unsubscribe=One-Click

Message

Content-Type
multipart/alternative; boundary=0d004860f5560098edae0ec6b2295ff41209a1d8f2f3aa333d644c8fe328
Date
Thu, 19 Nov 2026 16:00:00 +0000 (UTC)
From
Levels <[email protected]>
Mime-Version
1.0
Message-ID
<rSWItUiAR5GwvUB2WSoaVw@geopod-ismtpd-11>
Subject
Should you be taking peptides?

More from Levels

All 35 emails
Levels

What one extra drink does to your night

Levels

What we learned in our 3-year study

Levels

Why short sleep changes what you eat

Levels

The Marker You're Missing: GGT

Similar campaigns from other brands

Different brands running the same play. Compare any of them side by side.

TheFeed.

The oral, sports-legal way into peptides

Compare
Mars Men

The supplement industry is full of tricks

Compare
Arnold's Pump Club

Is anyone checking your supplements?

Compare
Elysium Health

What are doctors prescribing?

Compare

Archived for reference and commentary. Levels, its logos and content are the property of their respective owners; Inbox Archive claims no affiliation and has disabled all links. If you own this content and would like it removed, get in touch.